Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shield Therapeutics ( (GB:STX) ) just unveiled an announcement.
Shield Therapeutics reported a significant increase in revenues and prescription sales for the first half of 2025, driven by the strong performance of its product ACCRUFeR® in the U.S. and global markets. The company achieved substantial progress in international partnerships, including new licensing agreements and regulatory submissions, while maintaining its guidance to become cash flow positive by the end of 2025. These developments highlight Shield’s strategic efforts to expand its market presence and meet the growing demand for its iron deficiency treatment.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency with or without anemia through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company operates in the U.S. market through a collaboration with Viatris Inc., and has licensed its product to various partners for commercialization in Europe, Canada, China, Japan, and other regions.
Average Trading Volume: 2,804,225
Technical Sentiment Signal: Hold
Current Market Cap: £70.83M
See more data about STX stock on TipRanks’ Stock Analysis page.